• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Gary Liska Discusses Alere's Role in the STABLE study

Article

Gary Liska, with Alere Home Monitoring Inc, says Alere's commitment to patients' safety is why they supported the STABLE study.

Gary Liska, with Alere Home Monitoring Inc, says Alere’s commitment to patient safety is why they supported the STABLE study. They saw an opportunity with Medicare’s expansion of its coverage policy for self-testing, and decided to provide self-testing services to Medicare and practitioners.

Mr Liska also explains why the STABLE study results are so important.

“Within the last 3 years, there have been 5 clinical papers written on cost-effectiveness. The market remains very volatile right now, and clinicians, and particularly healthcare, is looking for the most cost-effective agent,” Mr Liska says. “The 5 studies that have been published are all consistent with a certain threshold of warfarin quality of between 65% and 73%, so those are thresholds that Alere looks at very carefully. It was really the impetus behind conducting this study.”

Related Videos
Joshua K. Sabari, MD
Nicoletta Colombo, MD, PhD
Khush Kharidia, MD
Jo Varshney, PhD, DVM, CEO and founder, VeriSIM Life
Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council
Harry Travis, BS Pharm, MBA, president at The Travis Group, LLC
 Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Chelsea Renfro, PharmD, research and engagement pharmacist, Vanderbilt Specialty Pharmacy
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.